Wednesday, 16 January 2008 08:03
Archive - Life Sciences Archive
BioFocus DPI, the services division of Galapagos NV, is to start work to uncover new cancer therapies under a £7.8 million collaborative programme with Belgian pharma firm, Janssen L.P.
Under the two-year programme – the company’s first in this area – the Great Chesterford firm will apply the its proprietary adenoviral platform to discover and validate novel targets in the field of oncology.
BioFocus DPI receives an upfront payment of €2.9m (£2.2m). However, in total it may receive additional research, acceptance, license and development fees of up to €7.6m (£5.7m) should certain predetermined criteria be achieved.
“This marks BioFocus DPI’s first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division,” said Onno van de Stolpe, chief executive officer of Galapagos.
BioFocus DPI said that target discovery in cutting edge in vitro assays may provide novel drug targets for cancer areas with an unmet medical need.
| |
Daily newsletter
Site Login
 |